Endocrine/metabolic

Mouse studies suggest inhibiting SGLT2 could help treat G6PC3 deficiency-induced neutropenia. In a mouse model of G6PC3 deficiency, the SGLT2 inhibitor Jardiance empagliflozin decreased granulocyte maturation arrest in the bone marrow and increased the numbers of circulating granulocytes, including neutrophils, compared with vehicle. Next steps could include testing SGLT2 inhibitors in other models of G6PC3 deficiency.

Boehringer Ingelheim GmbH and Eli Lilly and Co. market Jardiance for diabetes and have the product in Phase III testing for heart failure...